nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ORM1—Erlotinib—pancreatic cancer	0.068	0.0864	CbGbCtD
Propranolol—CYP1A1—Dacarbazine—pancreatic cancer	0.0567	0.072	CbGbCtD
Propranolol—CYP1A1—Tamoxifen—pancreatic cancer	0.0451	0.0573	CbGbCtD
Propranolol—CYP1A1—Erlotinib—pancreatic cancer	0.0383	0.0487	CbGbCtD
Propranolol—CYP3A7—Tamoxifen—pancreatic cancer	0.0361	0.0458	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0361	0.0458	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0277	0.0352	CbGbCtD
Propranolol—CYP3A7—Irinotecan—pancreatic cancer	0.0277	0.0352	CbGbCtD
Propranolol—CYP3A5—Tamoxifen—pancreatic cancer	0.0271	0.0344	CbGbCtD
Propranolol—CYP1A2—Dacarbazine—pancreatic cancer	0.0253	0.0322	CbGbCtD
Propranolol—CYP3A5—Erlotinib—pancreatic cancer	0.023	0.0292	CbGbCtD
Propranolol—CYP2C19—Tamoxifen—pancreatic cancer	0.0218	0.0277	CbGbCtD
Propranolol—CYP3A5—Irinotecan—pancreatic cancer	0.0208	0.0264	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0203	0.0258	CbGbCtD
Propranolol—CYP3A7—Docetaxel—pancreatic cancer	0.0203	0.0258	CbGbCtD
Propranolol—CYP3A7—Sunitinib—pancreatic cancer	0.0202	0.0257	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0202	0.0257	CbGbCtD
Propranolol—CYP1A2—Tamoxifen—pancreatic cancer	0.0201	0.0256	CbGbCtD
Propranolol—ABCB1—Tamoxifen—pancreatic cancer	0.0176	0.0224	CbGbCtD
Propranolol—CYP1A2—Erlotinib—pancreatic cancer	0.0171	0.0217	CbGbCtD
Propranolol—CYP2D6—Tamoxifen—pancreatic cancer	0.0166	0.0211	CbGbCtD
Propranolol—CYP3A5—Docetaxel—pancreatic cancer	0.0152	0.0193	CbGbCtD
Propranolol—ABCB1—Gemcitabine—pancreatic cancer	0.0152	0.0193	CbGbCtD
Propranolol—CYP3A5—Sunitinib—pancreatic cancer	0.0152	0.0193	CbGbCtD
Propranolol—ABCB1—Erlotinib—pancreatic cancer	0.015	0.019	CbGbCtD
Propranolol—CYP1A2—Fluorouracil—pancreatic cancer	0.0148	0.0188	CbGbCtD
Propranolol—CYP2D6—Erlotinib—pancreatic cancer	0.0141	0.0179	CbGbCtD
Propranolol—ABCB1—Irinotecan—pancreatic cancer	0.0135	0.0172	CbGbCtD
Propranolol—CYP3A4—Tamoxifen—pancreatic cancer	0.0106	0.0134	CbGbCtD
Propranolol—ABCB1—Docetaxel—pancreatic cancer	0.00991	0.0126	CbGbCtD
Propranolol—ABCB1—Sunitinib—pancreatic cancer	0.00986	0.0125	CbGbCtD
Propranolol—CYP3A4—Erlotinib—pancreatic cancer	0.00897	0.0114	CbGbCtD
Propranolol—CYP3A4—Irinotecan—pancreatic cancer	0.0081	0.0103	CbGbCtD
Propranolol—ABCB1—Doxorubicin—pancreatic cancer	0.00739	0.00938	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—pancreatic cancer	0.00696	0.00884	CbGbCtD
Propranolol—CYP3A4—Docetaxel—pancreatic cancer	0.00594	0.00754	CbGbCtD
Propranolol—CYP3A4—Sunitinib—pancreatic cancer	0.00591	0.00751	CbGbCtD
Propranolol—CYP3A4—Doxorubicin—pancreatic cancer	0.00443	0.00562	CbGbCtD
Propranolol—Carvedilol—HIF1A—pancreatic cancer	0.00144	0.713	CrCbGaD
Propranolol—Carvedilol—VEGFA—pancreatic cancer	0.00058	0.287	CrCbGaD
Propranolol—Dyspnoea—Sunitinib—pancreatic cancer	0.000321	0.00207	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.000319	0.00206	CcSEcCtD
Propranolol—Cough—Irinotecan—pancreatic cancer	0.000317	0.00205	CcSEcCtD
Propranolol—Dyspepsia—Sunitinib—pancreatic cancer	0.000317	0.00205	CcSEcCtD
Propranolol—Vascular purpura—Epirubicin—pancreatic cancer	0.000315	0.00203	CcSEcCtD
Propranolol—Decreased appetite—Sunitinib—pancreatic cancer	0.000313	0.00202	CcSEcCtD
Propranolol—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000311	0.00201	CcSEcCtD
Propranolol—Fatigue—Sunitinib—pancreatic cancer	0.00031	0.002	CcSEcCtD
Propranolol—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.00031	0.002	CcSEcCtD
Propranolol—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00031	0.002	CcSEcCtD
Propranolol—Cough—Gemcitabine—pancreatic cancer	0.000309	0.00199	CcSEcCtD
Propranolol—Pain—Sunitinib—pancreatic cancer	0.000308	0.00199	CcSEcCtD
Propranolol—Constipation—Sunitinib—pancreatic cancer	0.000308	0.00199	CcSEcCtD
Propranolol—Asthenia—Tamoxifen—pancreatic cancer	0.000302	0.00195	CcSEcCtD
Propranolol—Convulsion—Fluorouracil—pancreatic cancer	0.000302	0.00195	CcSEcCtD
Propranolol—Agranulocytosis—Docetaxel—pancreatic cancer	0.0003	0.00194	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000299	0.00193	CcSEcCtD
Propranolol—Asthenia—Erlotinib—pancreatic cancer	0.000298	0.00193	CcSEcCtD
Propranolol—Dermatitis exfoliative—Epirubicin—pancreatic cancer	0.000298	0.00193	CcSEcCtD
Propranolol—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000297	0.00192	CcSEcCtD
Propranolol—Infection—Irinotecan—pancreatic cancer	0.000295	0.0019	CcSEcCtD
Propranolol—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000294	0.0019	CcSEcCtD
Propranolol—Purpura—Epirubicin—pancreatic cancer	0.000292	0.00189	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—pancreatic cancer	0.000291	0.00188	CcSEcCtD
Propranolol—Nervous system disorder—Irinotecan—pancreatic cancer	0.000291	0.00188	CcSEcCtD
Propranolol—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000291	0.00188	CcSEcCtD
Propranolol—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000289	0.00187	CcSEcCtD
Propranolol—Hypoglycaemia—Epirubicin—pancreatic cancer	0.000288	0.00186	CcSEcCtD
Propranolol—Diarrhoea—Tamoxifen—pancreatic cancer	0.000288	0.00186	CcSEcCtD
Propranolol—Lethargy—Epirubicin—pancreatic cancer	0.000287	0.00185	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.000287	0.00185	CcSEcCtD
Propranolol—Infection—Gemcitabine—pancreatic cancer	0.000287	0.00185	CcSEcCtD
Propranolol—Pharyngitis—Docetaxel—pancreatic cancer	0.000286	0.00185	CcSEcCtD
Propranolol—Body temperature increased—Sunitinib—pancreatic cancer	0.000285	0.00184	CcSEcCtD
Propranolol—Abdominal pain—Sunitinib—pancreatic cancer	0.000285	0.00184	CcSEcCtD
Propranolol—Diarrhoea—Erlotinib—pancreatic cancer	0.000285	0.00184	CcSEcCtD
Propranolol—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000284	0.00183	CcSEcCtD
Propranolol—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000283	0.00183	CcSEcCtD
Propranolol—Infection—Fluorouracil—pancreatic cancer	0.000282	0.00182	CcSEcCtD
Propranolol—Skin disorder—Gemcitabine—pancreatic cancer	0.000281	0.00181	CcSEcCtD
Propranolol—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000279	0.0018	CcSEcCtD
Propranolol—Visual impairment—Docetaxel—pancreatic cancer	0.000278	0.0018	CcSEcCtD
Propranolol—Dizziness—Tamoxifen—pancreatic cancer	0.000278	0.0018	CcSEcCtD
Propranolol—Affect lability—Epirubicin—pancreatic cancer	0.000277	0.00179	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	0.000276	0.00178	CcSEcCtD
Propranolol—Dizziness—Erlotinib—pancreatic cancer	0.000275	0.00178	CcSEcCtD
Propranolol—Erythema multiforme—Docetaxel—pancreatic cancer	0.000273	0.00176	CcSEcCtD
Propranolol—Purpura—Doxorubicin—pancreatic cancer	0.00027	0.00174	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000269	0.00174	CcSEcCtD
Propranolol—Insomnia—Irinotecan—pancreatic cancer	0.000268	0.00173	CcSEcCtD
Propranolol—Cardiac disorder—Docetaxel—pancreatic cancer	0.000268	0.00173	CcSEcCtD
Propranolol—Cardiac arrest—Epirubicin—pancreatic cancer	0.000268	0.00173	CcSEcCtD
Propranolol—Vomiting—Tamoxifen—pancreatic cancer	0.000267	0.00173	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000267	0.00172	CcSEcCtD
Propranolol—Mood swings—Epirubicin—pancreatic cancer	0.000267	0.00172	CcSEcCtD
Propranolol—Paraesthesia—Irinotecan—pancreatic cancer	0.000266	0.00172	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—pancreatic cancer	0.000266	0.00172	CcSEcCtD
Propranolol—Hypersensitivity—Sunitinib—pancreatic cancer	0.000265	0.00171	CcSEcCtD
Propranolol—Rash—Tamoxifen—pancreatic cancer	0.000265	0.00171	CcSEcCtD
Propranolol—Dermatitis—Tamoxifen—pancreatic cancer	0.000265	0.00171	CcSEcCtD
Propranolol—Vomiting—Erlotinib—pancreatic cancer	0.000264	0.00171	CcSEcCtD
Propranolol—Dyspnoea—Irinotecan—pancreatic cancer	0.000264	0.00171	CcSEcCtD
Propranolol—Somnolence—Irinotecan—pancreatic cancer	0.000264	0.0017	CcSEcCtD
Propranolol—Rash—Erlotinib—pancreatic cancer	0.000262	0.00169	CcSEcCtD
Propranolol—Dermatitis—Erlotinib—pancreatic cancer	0.000262	0.00169	CcSEcCtD
Propranolol—Insomnia—Gemcitabine—pancreatic cancer	0.000261	0.00169	CcSEcCtD
Propranolol—Dyspepsia—Irinotecan—pancreatic cancer	0.000261	0.00169	CcSEcCtD
Propranolol—Paraesthesia—Gemcitabine—pancreatic cancer	0.000259	0.00168	CcSEcCtD
Propranolol—Asthenia—Sunitinib—pancreatic cancer	0.000258	0.00167	CcSEcCtD
Propranolol—Decreased appetite—Irinotecan—pancreatic cancer	0.000258	0.00167	CcSEcCtD
Propranolol—Dyspnoea—Gemcitabine—pancreatic cancer	0.000258	0.00166	CcSEcCtD
Propranolol—Insomnia—Fluorouracil—pancreatic cancer	0.000257	0.00166	CcSEcCtD
Propranolol—Somnolence—Gemcitabine—pancreatic cancer	0.000257	0.00166	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Propranolol—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Propranolol—Fatigue—Irinotecan—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Propranolol—Paraesthesia—Fluorouracil—pancreatic cancer	0.000255	0.00165	CcSEcCtD
Propranolol—Alopecia—Docetaxel—pancreatic cancer	0.000255	0.00165	CcSEcCtD
Propranolol—Constipation—Irinotecan—pancreatic cancer	0.000254	0.00164	CcSEcCtD
Propranolol—Pain—Irinotecan—pancreatic cancer	0.000254	0.00164	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000253	0.00164	CcSEcCtD
Propranolol—Dyspnoea—Fluorouracil—pancreatic cancer	0.000253	0.00164	CcSEcCtD
Propranolol—Mental disorder—Docetaxel—pancreatic cancer	0.000253	0.00163	CcSEcCtD
Propranolol—Somnolence—Fluorouracil—pancreatic cancer	0.000253	0.00163	CcSEcCtD
Propranolol—Erythema—Docetaxel—pancreatic cancer	0.000251	0.00162	CcSEcCtD
Propranolol—Decreased appetite—Gemcitabine—pancreatic cancer	0.000251	0.00162	CcSEcCtD
Propranolol—Dyspepsia—Fluorouracil—pancreatic cancer	0.00025	0.00161	CcSEcCtD
Propranolol—Nausea—Tamoxifen—pancreatic cancer	0.00025	0.00161	CcSEcCtD
Propranolol—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000249	0.00161	CcSEcCtD
Propranolol—Fatigue—Gemcitabine—pancreatic cancer	0.000249	0.00161	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000248	0.0016	CcSEcCtD
Propranolol—Pain—Gemcitabine—pancreatic cancer	0.000247	0.0016	CcSEcCtD
Propranolol—Constipation—Gemcitabine—pancreatic cancer	0.000247	0.0016	CcSEcCtD
Propranolol—Nausea—Erlotinib—pancreatic cancer	0.000247	0.0016	CcSEcCtD
Propranolol—Decreased appetite—Fluorouracil—pancreatic cancer	0.000247	0.00159	CcSEcCtD
Propranolol—Mood swings—Doxorubicin—pancreatic cancer	0.000247	0.00159	CcSEcCtD
Propranolol—Diarrhoea—Sunitinib—pancreatic cancer	0.000246	0.00159	CcSEcCtD
Propranolol—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000245	0.00158	CcSEcCtD
Propranolol—Pain—Fluorouracil—pancreatic cancer	0.000243	0.00157	CcSEcCtD
Propranolol—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000243	0.00157	CcSEcCtD
Propranolol—Dizziness—Sunitinib—pancreatic cancer	0.000238	0.00154	CcSEcCtD
Propranolol—Body temperature increased—Irinotecan—pancreatic cancer	0.000234	0.00151	CcSEcCtD
Propranolol—Abdominal pain—Irinotecan—pancreatic cancer	0.000234	0.00151	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000234	0.00151	CcSEcCtD
Propranolol—Bronchitis—Epirubicin—pancreatic cancer	0.000234	0.00151	CcSEcCtD
Propranolol—Vomiting—Sunitinib—pancreatic cancer	0.000229	0.00148	CcSEcCtD
Propranolol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000228	0.00147	CcSEcCtD
Propranolol—Neutropenia—Epirubicin—pancreatic cancer	0.000227	0.00147	CcSEcCtD
Propranolol—Rash—Sunitinib—pancreatic cancer	0.000227	0.00147	CcSEcCtD
Propranolol—Dermatitis—Sunitinib—pancreatic cancer	0.000227	0.00146	CcSEcCtD
Propranolol—Urticaria—Fluorouracil—pancreatic cancer	0.000226	0.00146	CcSEcCtD
Propranolol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000225	0.00145	CcSEcCtD
Propranolol—Cough—Docetaxel—pancreatic cancer	0.000219	0.00142	CcSEcCtD
Propranolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000219	0.00141	CcSEcCtD
Propranolol—Convulsion—Docetaxel—pancreatic cancer	0.000218	0.00141	CcSEcCtD
Propranolol—Infestation NOS—Epirubicin—pancreatic cancer	0.000217	0.0014	CcSEcCtD
Propranolol—Infestation—Epirubicin—pancreatic cancer	0.000217	0.0014	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—pancreatic cancer	0.000216	0.0014	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000215	0.00139	CcSEcCtD
Propranolol—Nausea—Sunitinib—pancreatic cancer	0.000214	0.00138	CcSEcCtD
Propranolol—Asthenia—Irinotecan—pancreatic cancer	0.000213	0.00137	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000212	0.00137	CcSEcCtD
Propranolol—Neutropenia—Doxorubicin—pancreatic cancer	0.00021	0.00136	CcSEcCtD
Propranolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000209	0.00135	CcSEcCtD
Propranolol—Asthenia—Gemcitabine—pancreatic cancer	0.000207	0.00134	CcSEcCtD
Propranolol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000205	0.00132	CcSEcCtD
Propranolol—Infection—Docetaxel—pancreatic cancer	0.000204	0.00132	CcSEcCtD
Propranolol—Diarrhoea—Irinotecan—pancreatic cancer	0.000203	0.00131	CcSEcCtD
Propranolol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000202	0.00131	CcSEcCtD
Propranolol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000201	0.0013	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—pancreatic cancer	0.000201	0.0013	CcSEcCtD
Propranolol—Infestation—Doxorubicin—pancreatic cancer	0.000201	0.0013	CcSEcCtD
Propranolol—Skin disorder—Docetaxel—pancreatic cancer	0.000199	0.00129	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000199	0.00128	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—pancreatic cancer	0.000198	0.00128	CcSEcCtD
Propranolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000198	0.00128	CcSEcCtD
Propranolol—Dizziness—Irinotecan—pancreatic cancer	0.000196	0.00127	CcSEcCtD
Propranolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000194	0.00126	CcSEcCtD
Propranolol—Pharyngitis—Epirubicin—pancreatic cancer	0.000193	0.00125	CcSEcCtD
Propranolol—Vomiting—Irinotecan—pancreatic cancer	0.000189	0.00122	CcSEcCtD
Propranolol—Dizziness—Fluorouracil—pancreatic cancer	0.000188	0.00121	CcSEcCtD
Propranolol—Visual impairment—Epirubicin—pancreatic cancer	0.000188	0.00121	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Propranolol—Rash—Irinotecan—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Propranolol—Dermatitis—Irinotecan—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Propranolol—Insomnia—Docetaxel—pancreatic cancer	0.000185	0.0012	CcSEcCtD
Propranolol—Paraesthesia—Docetaxel—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Propranolol—Vomiting—Gemcitabine—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—pancreatic cancer	0.000183	0.00118	CcSEcCtD
Propranolol—Dyspnoea—Docetaxel—pancreatic cancer	0.000183	0.00118	CcSEcCtD
Propranolol—Somnolence—Docetaxel—pancreatic cancer	0.000182	0.00118	CcSEcCtD
Propranolol—Rash—Gemcitabine—pancreatic cancer	0.000182	0.00118	CcSEcCtD
Propranolol—Dermatitis—Gemcitabine—pancreatic cancer	0.000182	0.00118	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000181	0.00117	CcSEcCtD
Propranolol—Vomiting—Fluorouracil—pancreatic cancer	0.000181	0.00117	CcSEcCtD
Propranolol—Dyspepsia—Docetaxel—pancreatic cancer	0.00018	0.00117	CcSEcCtD
Propranolol—Rash—Fluorouracil—pancreatic cancer	0.000179	0.00116	CcSEcCtD
Propranolol—Dermatitis—Fluorouracil—pancreatic cancer	0.000179	0.00116	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—pancreatic cancer	0.000179	0.00115	CcSEcCtD
Propranolol—Decreased appetite—Docetaxel—pancreatic cancer	0.000178	0.00115	CcSEcCtD
Propranolol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000177	0.00114	CcSEcCtD
Propranolol—Fatigue—Docetaxel—pancreatic cancer	0.000177	0.00114	CcSEcCtD
Propranolol—Nausea—Irinotecan—pancreatic cancer	0.000176	0.00114	CcSEcCtD
Propranolol—Pain—Docetaxel—pancreatic cancer	0.000175	0.00113	CcSEcCtD
Propranolol—Constipation—Docetaxel—pancreatic cancer	0.000175	0.00113	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—pancreatic cancer	0.000174	0.00112	CcSEcCtD
Propranolol—Alopecia—Epirubicin—pancreatic cancer	0.000172	0.00111	CcSEcCtD
Propranolol—Nausea—Gemcitabine—pancreatic cancer	0.000172	0.00111	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—pancreatic cancer	0.000171	0.0011	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00017	0.0011	CcSEcCtD
Propranolol—Erythema—Epirubicin—pancreatic cancer	0.000169	0.00109	CcSEcCtD
Propranolol—Nausea—Fluorouracil—pancreatic cancer	0.000169	0.00109	CcSEcCtD
Propranolol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000168	0.00108	CcSEcCtD
Propranolol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000167	0.00108	CcSEcCtD
Propranolol—Abdominal pain—Docetaxel—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Propranolol—Body temperature increased—Docetaxel—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—pancreatic cancer	0.000159	0.00103	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—pancreatic cancer	0.000158	0.00102	CcSEcCtD
Propranolol—Erythema—Doxorubicin—pancreatic cancer	0.000157	0.00101	CcSEcCtD
Propranolol—Agitation—Epirubicin—pancreatic cancer	0.000156	0.00101	CcSEcCtD
Propranolol—Vertigo—Epirubicin—pancreatic cancer	0.000152	0.000983	CcSEcCtD
Propranolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000151	0.000975	CcSEcCtD
Propranolol—Cough—Epirubicin—pancreatic cancer	0.000148	0.000955	CcSEcCtD
Propranolol—Asthenia—Docetaxel—pancreatic cancer	0.000147	0.00095	CcSEcCtD
Propranolol—Convulsion—Epirubicin—pancreatic cancer	0.000147	0.000948	CcSEcCtD
Propranolol—Agitation—Doxorubicin—pancreatic cancer	0.000144	0.00093	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000143	0.000925	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—pancreatic cancer	0.000141	0.00091	CcSEcCtD
Propranolol—Diarrhoea—Docetaxel—pancreatic cancer	0.00014	0.000906	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000138	0.000893	CcSEcCtD
Propranolol—Infection—Epirubicin—pancreatic cancer	0.000137	0.000887	CcSEcCtD
Propranolol—Cough—Doxorubicin—pancreatic cancer	0.000137	0.000884	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—pancreatic cancer	0.000136	0.000877	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000136	0.000876	CcSEcCtD
Propranolol—Dizziness—Docetaxel—pancreatic cancer	0.000136	0.000876	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—pancreatic cancer	0.000134	0.000867	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000133	0.000856	CcSEcCtD
Propranolol—Vomiting—Docetaxel—pancreatic cancer	0.00013	0.000842	CcSEcCtD
Propranolol—Rash—Docetaxel—pancreatic cancer	0.000129	0.000835	CcSEcCtD
Propranolol—Dermatitis—Docetaxel—pancreatic cancer	0.000129	0.000834	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000128	0.000826	CcSEcCtD
Propranolol—Infection—Doxorubicin—pancreatic cancer	0.000127	0.000821	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000125	0.00081	CcSEcCtD
Propranolol—Insomnia—Epirubicin—pancreatic cancer	0.000125	0.000808	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—pancreatic cancer	0.000124	0.000803	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—pancreatic cancer	0.000124	0.000802	CcSEcCtD
Propranolol—Dyspnoea—Epirubicin—pancreatic cancer	0.000123	0.000796	CcSEcCtD
Propranolol—Somnolence—Epirubicin—pancreatic cancer	0.000123	0.000794	CcSEcCtD
Propranolol—Nausea—Docetaxel—pancreatic cancer	0.000122	0.000786	CcSEcCtD
Propranolol—Dyspepsia—Epirubicin—pancreatic cancer	0.000122	0.000786	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—pancreatic cancer	0.00012	0.000776	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000119	0.000771	CcSEcCtD
Propranolol—Fatigue—Epirubicin—pancreatic cancer	0.000119	0.00077	CcSEcCtD
Propranolol—Pain—Epirubicin—pancreatic cancer	0.000118	0.000764	CcSEcCtD
Propranolol—Constipation—Epirubicin—pancreatic cancer	0.000118	0.000764	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—pancreatic cancer	0.000116	0.000747	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000115	0.000742	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000114	0.000737	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—pancreatic cancer	0.000114	0.000735	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000113	0.00073	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000113	0.000727	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—pancreatic cancer	0.000111	0.000718	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00011	0.000713	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—pancreatic cancer	0.00011	0.000712	CcSEcCtD
Propranolol—Urticaria—Epirubicin—pancreatic cancer	0.00011	0.000709	CcSEcCtD
Propranolol—Pain—Doxorubicin—pancreatic cancer	0.000109	0.000707	CcSEcCtD
Propranolol—Constipation—Doxorubicin—pancreatic cancer	0.000109	0.000707	CcSEcCtD
Propranolol—Abdominal pain—Epirubicin—pancreatic cancer	0.000109	0.000706	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—pancreatic cancer	0.000109	0.000706	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000105	0.000676	CcSEcCtD
Propranolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000102	0.000658	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—pancreatic cancer	0.000102	0.000656	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—pancreatic cancer	0.000101	0.000653	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000101	0.000653	CcSEcCtD
Propranolol—Asthenia—Epirubicin—pancreatic cancer	9.92e-05	0.000641	CcSEcCtD
Propranolol—Diarrhoea—Epirubicin—pancreatic cancer	9.46e-05	0.000611	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—pancreatic cancer	9.43e-05	0.000609	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—pancreatic cancer	9.18e-05	0.000593	CcSEcCtD
Propranolol—Dizziness—Epirubicin—pancreatic cancer	9.15e-05	0.000591	CcSEcCtD
Propranolol—Vomiting—Epirubicin—pancreatic cancer	8.79e-05	0.000568	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—pancreatic cancer	8.76e-05	0.000565	CcSEcCtD
Propranolol—Rash—Epirubicin—pancreatic cancer	8.72e-05	0.000563	CcSEcCtD
Propranolol—Dermatitis—Epirubicin—pancreatic cancer	8.71e-05	0.000563	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—pancreatic cancer	8.46e-05	0.000546	CcSEcCtD
Propranolol—Nausea—Epirubicin—pancreatic cancer	8.21e-05	0.00053	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—pancreatic cancer	8.14e-05	0.000525	CcSEcCtD
Propranolol—Rash—Doxorubicin—pancreatic cancer	8.07e-05	0.000521	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—pancreatic cancer	8.06e-05	0.000521	CcSEcCtD
Propranolol—Nausea—Doxorubicin—pancreatic cancer	7.6e-05	0.000491	CcSEcCtD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.03e-06	0.000162	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	9.01e-06	0.000162	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CD44—pancreatic cancer	9e-06	0.000161	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—AKT1—pancreatic cancer	8.97e-06	0.000161	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.95e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	8.95e-06	0.00016	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	8.95e-06	0.00016	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	8.93e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	8.92e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—KRAS—pancreatic cancer	8.91e-06	0.00016	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	8.86e-06	0.000159	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GCG—pancreatic cancer	8.84e-06	0.000159	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	8.75e-06	0.000157	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—TYMS—pancreatic cancer	8.74e-06	0.000157	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—APOE—pancreatic cancer	8.73e-06	0.000157	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GCG—pancreatic cancer	8.63e-06	0.000155	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KDR—pancreatic cancer	8.56e-06	0.000153	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—SRC—pancreatic cancer	8.52e-06	0.000153	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	8.51e-06	0.000153	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CD44—pancreatic cancer	8.48e-06	0.000152	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	8.43e-06	0.000151	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	8.32e-06	0.000149	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—STK11—pancreatic cancer	8.31e-06	0.000149	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—pancreatic cancer	8.3e-06	0.000149	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	8.26e-06	0.000148	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	8.24e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	8.24e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	8.24e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	8.24e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—STAT3—pancreatic cancer	8.22e-06	0.000147	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NRAS—pancreatic cancer	8.2e-06	0.000147	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	8.18e-06	0.000147	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	8.15e-06	0.000146	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	8.14e-06	0.000146	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GCG—pancreatic cancer	8.13e-06	0.000146	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—STK11—pancreatic cancer	8.11e-06	0.000145	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.07e-06	0.000145	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	8.06e-06	0.000145	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	8.06e-06	0.000145	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	8.06e-06	0.000145	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	7.97e-06	0.000143	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CB—pancreatic cancer	7.93e-06	0.000142	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	7.88e-06	0.000141	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	7.88e-06	0.000141	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.8e-06	0.00014	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGF—pancreatic cancer	7.79e-06	0.00014	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.67e-06	0.000138	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—STK11—pancreatic cancer	7.65e-06	0.000137	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MYC—pancreatic cancer	7.64e-06	0.000137	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TGFB1—pancreatic cancer	7.62e-06	0.000137	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCL8—pancreatic cancer	7.62e-06	0.000137	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—HRAS—pancreatic cancer	7.57e-06	0.000136	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.55e-06	0.000135	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—APOE—pancreatic cancer	7.52e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	7.51e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EGFR—pancreatic cancer	7.47e-06	0.000134	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—pancreatic cancer	7.36e-06	0.000132	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	7.34e-06	0.000132	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CASP3—pancreatic cancer	7.29e-06	0.000131	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	7.24e-06	0.00013	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	7.2e-06	0.000129	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CD44—pancreatic cancer	7.19e-06	0.000129	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	7.19e-06	0.000129	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	7.18e-06	0.000129	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.18e-06	0.000129	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	7.16e-06	0.000128	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—TYMS—pancreatic cancer	7.15e-06	0.000128	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—pancreatic cancer	7.13e-06	0.000128	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—pancreatic cancer	7.12e-06	0.000128	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—APOE—pancreatic cancer	7.11e-06	0.000127	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—pancreatic cancer	7.1e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	7.09e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	7.09e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—pancreatic cancer	7.06e-06	0.000127	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.04e-06	0.000126	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CTNNB1—pancreatic cancer	7.03e-06	0.000126	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.02e-06	0.000126	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—TYMS—pancreatic cancer	6.98e-06	0.000125	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.97e-06	0.000125	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	6.94e-06	0.000124	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	6.93e-06	0.000124	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MMP9—pancreatic cancer	6.89e-06	0.000124	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GCG—pancreatic cancer	6.89e-06	0.000124	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.86e-06	0.000123	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—pancreatic cancer	6.85e-06	0.000123	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	6.79e-06	0.000122	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	6.78e-06	0.000122	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.73e-06	0.000121	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—pancreatic cancer	6.68e-06	0.00012	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TYMS—pancreatic cancer	6.58e-06	0.000118	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARG—pancreatic cancer	6.55e-06	0.000117	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.52e-06	0.000117	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—pancreatic cancer	6.48e-06	0.000116	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—STK11—pancreatic cancer	6.48e-06	0.000116	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	6.41e-06	0.000115	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	6.37e-06	0.000114	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SRC—pancreatic cancer	6.35e-06	0.000114	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	6.31e-06	0.000113	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—pancreatic cancer	6.27e-06	0.000112	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.23e-06	0.000112	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—pancreatic cancer	6.22e-06	0.000112	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—pancreatic cancer	6.21e-06	0.000111	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARG—pancreatic cancer	6.19e-06	0.000111	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	6.19e-06	0.000111	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	6.18e-06	0.000111	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	6.13e-06	0.00011	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	6.11e-06	0.00011	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.08e-06	0.000109	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	6.07e-06	0.000109	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	6.04e-06	0.000108	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	6.03e-06	0.000108	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—pancreatic cancer	6e-06	0.000108	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	5.97e-06	0.000107	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	5.94e-06	0.000106	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	5.9e-06	0.000106	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	5.86e-06	0.000105	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—APOE—pancreatic cancer	5.82e-06	0.000104	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	5.81e-06	0.000104	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	5.8e-06	0.000104	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	5.77e-06	0.000103	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	5.73e-06	0.000103	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—pancreatic cancer	5.69e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	5.68e-06	0.000102	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	5.68e-06	0.000102	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—APOE—pancreatic cancer	5.68e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	5.65e-06	0.000101	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	5.64e-06	0.000101	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	5.61e-06	0.000101	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	5.6e-06	0.0001	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TYMS—pancreatic cancer	5.57e-06	9.99e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	5.57e-06	9.99e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	5.55e-06	9.96e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CD44—pancreatic cancer	5.55e-06	9.94e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	5.53e-06	9.92e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.51e-06	9.87e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	5.49e-06	9.84e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	5.48e-06	9.82e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	5.46e-06	9.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	5.41e-06	9.7e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	5.37e-06	9.63e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	5.35e-06	9.6e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—APOE—pancreatic cancer	5.35e-06	9.59e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	5.34e-06	9.57e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	5.32e-06	9.54e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GCG—pancreatic cancer	5.32e-06	9.53e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—pancreatic cancer	5.3e-06	9.5e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	5.26e-06	9.43e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	5.25e-06	9.41e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	5.25e-06	9.41e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	5.22e-06	9.36e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	5.21e-06	9.34e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	5.2e-06	9.33e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—pancreatic cancer	5.15e-06	9.24e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.12e-06	9.19e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	5.09e-06	9.13e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARG—pancreatic cancer	5.07e-06	9.08e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	5.06e-06	9.07e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—STK11—pancreatic cancer	5e-06	8.96e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	4.95e-06	8.88e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARG—pancreatic cancer	4.94e-06	8.87e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	4.93e-06	8.84e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	4.91e-06	8.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	4.88e-06	8.75e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—pancreatic cancer	4.87e-06	8.73e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	4.87e-06	8.73e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SRC—pancreatic cancer	4.84e-06	8.68e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	4.83e-06	8.67e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.83e-06	8.66e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	4.82e-06	8.64e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	4.77e-06	8.56e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	4.76e-06	8.54e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	4.71e-06	8.45e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—pancreatic cancer	4.68e-06	8.38e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	4.67e-06	8.37e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.66e-06	8.35e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	4.66e-06	8.35e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	4.61e-06	8.27e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	4.53e-06	8.13e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—APOE—pancreatic cancer	4.53e-06	8.13e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	4.52e-06	8.11e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.5e-06	8.08e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—pancreatic cancer	4.5e-06	8.06e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	4.47e-06	8.02e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.44e-06	7.95e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.43e-06	7.95e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.42e-06	7.93e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	4.39e-06	7.87e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	4.38e-06	7.85e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.34e-06	7.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—pancreatic cancer	4.34e-06	7.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	4.33e-06	7.76e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.3e-06	7.71e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.29e-06	7.69e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—pancreatic cancer	4.25e-06	7.62e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.24e-06	7.61e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	4.24e-06	7.61e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	4.19e-06	7.51e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	4.1e-06	7.35e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.09e-06	7.33e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	4.02e-06	7.21e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	4.01e-06	7.19e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—pancreatic cancer	3.99e-06	7.15e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	3.95e-06	7.08e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.95e-06	7.08e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.93e-06	7.04e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.89e-06	6.97e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	3.85e-06	6.9e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	3.77e-06	6.75e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	3.72e-06	6.68e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.7e-06	6.63e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.68e-06	6.6e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.67e-06	6.57e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	3.64e-06	6.53e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.6e-06	6.45e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—pancreatic cancer	3.58e-06	6.43e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—pancreatic cancer	3.58e-06	6.42e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—pancreatic cancer	3.56e-06	6.39e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.56e-06	6.39e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—APOE—pancreatic cancer	3.5e-06	6.27e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.48e-06	6.25e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.48e-06	6.23e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	3.41e-06	6.11e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—pancreatic cancer	3.39e-06	6.08e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.2e-06	5.73e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.17e-06	5.69e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.16e-06	5.66e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	3.14e-06	5.64e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.13e-06	5.62e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.11e-06	5.57e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	3.08e-06	5.52e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.05e-06	5.46e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	3.01e-06	5.39e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	3e-06	5.37e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.77e-06	4.98e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.71e-06	4.86e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.59e-06	4.65e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.45e-06	4.4e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.45e-06	4.39e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.42e-06	4.34e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.4e-06	4.3e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.39e-06	4.29e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.26e-06	4.04e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.09e-06	3.75e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—pancreatic cancer	2e-06	3.59e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—pancreatic cancer	1.95e-06	3.51e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.84e-06	3.3e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.56e-06	2.8e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.47e-06	2.64e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.2e-06	2.16e-05	CbGpPWpGaD
